Banque Cantonale Vaudoise Purchases 451 Shares of Natera, Inc. (NASDAQ:NTRA)

Banque Cantonale Vaudoise grew its position in Natera, Inc. (NASDAQ:NTRA) by 6.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,235 shares of the medical research company’s stock after purchasing an additional 451 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Natera were worth $662,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of NTRA. RiverPark Advisors LLC purchased a new position in shares of Natera during the 4th quarter valued at $27,000. Principal Securities Inc. purchased a new position in shares of Natera in the fourth quarter valued at about $32,000. Oliver Lagore Vanvalin Investment Group boosted its stake in shares of Natera by 109.3% in the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after acquiring an additional 389 shares during the period. CWM LLC grew its position in shares of Natera by 41.8% during the fourth quarter. CWM LLC now owns 1,867 shares of the medical research company’s stock worth $117,000 after purchasing an additional 550 shares in the last quarter. Finally, First Horizon Advisors Inc. raised its stake in Natera by 36.1% during the 4th quarter. First Horizon Advisors Inc. now owns 2,089 shares of the medical research company’s stock valued at $131,000 after purchasing an additional 554 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Steven Leonard Chapman sold 6,105 shares of the business’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $111.61, for a total value of $681,379.05. Following the completion of the transaction, the chief executive officer now directly owns 213,351 shares of the company’s stock, valued at approximately $23,812,105.11. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, insider Jonathan Sheena sold 447 shares of the stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $90.22, for a total transaction of $40,328.34. Following the completion of the sale, the insider now owns 347,731 shares of the company’s stock, valued at $31,372,290.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Steven Leonard Chapman sold 6,105 shares of Natera stock in a transaction on Monday, June 17th. The stock was sold at an average price of $111.61, for a total transaction of $681,379.05. Following the completion of the transaction, the chief executive officer now directly owns 213,351 shares in the company, valued at $23,812,105.11. The disclosure for this sale can be found here. Insiders sold a total of 185,988 shares of company stock worth $17,799,622 over the last 90 days. Company insiders own 7.60% of the company’s stock.

Natera Stock Down 0.1 %

Natera stock opened at $107.11 on Friday. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $117.23. The company’s 50-day moving average is $102.42 and its 200 day moving average is $84.01. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.12 and a quick ratio of 3.98.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.16. The firm had revenue of $367.70 million for the quarter, compared to the consensus estimate of $316.31 million. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The company’s revenue for the quarter was up 52.1% on a year-over-year basis. During the same period in the prior year, the business posted ($1.23) earnings per share. Equities research analysts anticipate that Natera, Inc. will post -2.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on NTRA shares. BTIG Research increased their price objective on shares of Natera from $100.00 to $125.00 and gave the company a “buy” rating in a report on Monday, May 13th. Jefferies Financial Group assumed coverage on shares of Natera in a research note on Monday, June 3rd. They issued a “buy” rating and a $142.00 price target on the stock. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a report on Friday, May 17th. Canaccord Genuity Group lifted their target price on Natera from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, May 10th. Finally, Craig Hallum initiated coverage on Natera in a research note on Monday, April 8th. They set a “buy” rating and a $117.00 price target for the company. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $101.19.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.